02/06/2026
PHAEurope was pleased to be represented by Hall Skaara at the 4th EU-PFF Patient Summit in Brussels, marking the 10th anniversary of the European Pulmonary Fibrosis Federation (EU-PFF).
Prior to the summit, Hall also participated in the European Lung Health Group (ELHG) face-to-face meeting, where both EU-PFF and PHAEurope (as ELHG members) contribute to strengthening collaboration across respiratory and pulmonary vascular diseases.
The summit highlighted many shared challenges faced by the pulmonary fibrosis (PF) and pulmonary hypertension (PH) communities, including delayed diagnosis, access to specialist care, patient empowerment, and meaningful involvement in research and policy development. As pulmonary fibrosis can lead to Group 3 PH, closer cooperation between our communities is particularly important.
Discussions also focused on treatment innovation. While only two therapies are currently approved for PF, a growing number of clinical trials are exploring new approaches, some of which may have relevance for both PF and PH patients in the future. Sessions on genetics, hereditary disease, and family support further reinforced the importance of holistic, patient-centred care.
The summit provided valuable opportunities to exchange experiences, identify common priorities, and strengthen partnerships across Europe. We thank EU-PFF for an inspiring event and look forward to continued collaboration in advancing care, research, and advocacy for patients living with PF and PH.
➡Read full article here: https://www.phaeurope.org/news/eu-pff-summit-report/
European Pulmonary Fibrosis Federation